Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias

A. M. Carella, E. Pungolino, G. Piatti, E. Gaozza, S. Nati, M. Spriano, D. Giordano, T. D'Amico, E. Damasio

Research output: Contribution to journalArticlepeer-review

Abstract

13 Patients with refractory or relapsed acute lymphoblastic leukemia (ALL) and 7 patients with acute myeloid leukemia (AML) were treated with a regimen that included idarubicin 12 mg/m2 intravenously daily for 3 d plus cytarabine 2 g/m2 by infusion over 3 hours daily for 3 d. There were 10 remissions (ALL:7; AML:3) in the 15 relapsed patients and 4 (ALL:3) in the 5 patients with primary refractory disease. Severe myelosuppression was observed in all patients. Toxicity of this regimen caused nausea and vomiting, infections and/or liver enzymes increase. Cardiac toxicity was not observed. 2 Patients died in aplasia of Gram-negative septicemia and brain hemorrhage. In conclusion, the combination of idarubicin and intermediate-dose cytarabine (IDARA-C) seems to be highly effective and sufficiently well-tolerated for the treatment of refractory and relapsed acute leukemias.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalEuropean Journal of Haematology
Volume43
Issue number4
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias'. Together they form a unique fingerprint.

Cite this